Halozyme Therapeutics strengthens management team
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics, a US biopharmaceutical company developing and commercialising products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets, has appointed Dr Patrick O'Connor vice-president of research, Dr Michael LaBarre vice-president of product development, and James Cartoni vice-president of legal. Dr O'Connor joins from Ardea Biosciences, where he was senior vice-president and chief scientific officer. Dr LaBarre previously served as vice-president of product development at Paramount BioSciences, while Mr Cartoni was a partner at the law firm DLA Piper.